tbuckley/cabot-search huggingface dataset:
Trauma and Psychosis: An Analysis of the National Comorbidity Survey
Authors: Mark Shevlin
Journal: American Journal of Psychiatry (2007)

Objective: The authors hypothesized that the likelihood of psychosis classification would increase with traumatic experiences. Method: Data from the National Comorbidity Survey were used to estimate the relationship between interpersonal trauma and the likelihood of a classification of psychosis. Results: Childhood physical abuse predicted psychosis, and there was a significant cumulative relationship between trauma and psychosis, with number of trauma types experienced increasing the probability of psychosis. Conclusions: Overall, physical abuse predicted psychosis. In addition, a significant gender-by-rape interaction was observed, with rape having higher predictive value for psychosis in male subjects.
Botulism Cases Rise In 1963
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adipopenia, among the nutritional parameters, is the rapid screening tool that best correlates with mortality in decompensated cirrhotic patients: results of a prospective study
Authors: Massimo De Luca, Luigi Addario, Anna Lombardi, Michele Imparato, Luca Fontanella, Marco Addario, Desiree Picascia, Giuseppe Di Costanzo, Antonio Ascione
Journal: Journal of Hepatology (2020)
Abstract 1221: Mitomycin C induces programed cell death ligand 1 overexpression but enhances anticancer immunity in none small cell lung cancer
Authors: Min Luo
Journal: Cancer Research (2019)

Abstract Blockade of the checkpoint inhibitor programmed death 1 ligand (PDL1) has demonstrated remarkable success in the clinic for the treatment of cancer; however, a majority of tumors are progressive with low response rate. To enhance the efficacy of PDL1 blockade immunotherapies, we tried to combine chemotherapy capable of enhancing antitumor immunity. Here, we screened that tumor cells with MMC pre-treatment was significantly killed by co-cultured lymphocytes than without ones. Indeed, tumor cells treated with MMC showed the increased release of granzyme B and TNF-α. And tumor lysis was enhanced by combined with PD1 Ab in vitro. Mice treated with both anti-PDL1 and MMC showed an improved overall survival and inhibition within the tumor, indicating that this combination improves the overall quality of the immune response generated. Mechanically, MMC was observed to upregulate PDL1 expression in a concentration and time manner. MMC activated c-JUN to bind with PDL1 promoter and recruited its co-factor, STAT3 to accelerate PDL1 expression. MMC induced an IFN-γ independent signature within the tumor cell, and ERK signaling pathway was activated. A reason for its enhancement in antitumor immunity was the high expression of MHC-I after MMC treatment which attracted more CD8+ T cells. These findings identified a potential mechanism for the observed benefit of combining MMC and PDL1 blockade, in which MMC induces PDL1 upregulation and MCH-I high expression, thereby converting the tumor cell into an immunogenic one, when block PDL1, the antitumor response was enhanced. Citation Format: Min Luo. Mitomycin C induces programed cell death ligand 1 overexpression but enhances anticancer immunity in none small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1221.
Abstract 33: A Meta-analysis Of Three Genome-wide Association Studies Identifies A Novel Susceptibility Locus For Kawasaki Disease.
Authors: Todd A Johnson, Jer-Yuarn Wu, Dankyu Yoon, Akira Hata, Michiaki Kubo, Atsushi Takahashi, Tatsuhiko Tsunoda, Kouichi Ozaki, Toshihiro Tanaka, Chien-Hsiun Chen, Yi-Ching Lee, Li-Ching Chang, Chun-Ping Chang, Young Mi Hong, Gi Young Jang, Sin Weon Yun, Jeong Jin Yu, Kyung-Yil Lee, Jae-Jung Kim, Jong-Keuk Lee, Yuan-Tsong Chen, Yoshihiro Onouchi
Journal: Circulation (2015)

Background: Although genome-wide association studies (GWAS) have conclusively identified several susceptibility genes / loci for Kawasaki disease (KD), a large part of the genetic etiology of this disease have not been unraveled and, above all, its marked predilection for East Asian populations have not been explained. Objective: To identify genetic variants commonly associated with KD in the East Asian populations, we conducted a meta-analysis of three GWASes from Japan, Korea and Taiwan. Methods: In the GWAS analyses, we genotyped 6322 subjects (1236 cases and 5086 controls) using either Illumina 550K or Affymetrix SNP 6.0 platforms and then imputed untyped genotypes using Impute2 or minimac software with 1000 Genomes Project’s East Asian population (JPT, CHB and CHS) reference haplotype data. We then performed a meta-analysis using a weighted-average method with inverse-variance weights and selected representative SNPs in 49 top associated loci, which were then genotyped in 4798 independent subjects (2151 cases and 2747 controls). Finally, we combined the data for the three GWASes and follow up studies in a meta-analysis. Results: SNPs within previously identified susceptibility loci showed significant association in the meta-analysis of the GWASes (ITPKC: rs28493229, P = 3.07 x 10-9; CASP3: rs2720377, P = 2.66 x 10-9; BLK: rs2736340, P = 1.23 x 10-16; CD40: rs1883832, P = 1.76 x 10-8; HLA class2: rs189914842, P = 4.57 x 10-11). In a meta-analysis of the three GWASes and follow-up studies, we observed a genome-wide significant level of association at a SNP in a chromosomal region different from the six known loci (P = 6.49 x 10-9). Conclusion: The meta-analysis of three GWAses and follow-up studies successfully identified a new SNP significantly associated with KD. Further investigation of the region where the SNP is located toward specification of the susceptibility gene, the responsible variant, as well as its effect on gene function is warranted. Acknowledgement: T.A.J., J.Y.W. and D.Y. equally contributed to this work and J.K.L., Y.T.C., and Y.O. are co-directing this project.
Elastofibroma Dorsi
Authors: Robert K. Brown, Kevin P. Clearkin, Kijin Nakachi, Claude O. Burdick
Journal: New England Journal of Medicine (1966)

IN 1961 Järvi and Saxén1 reported 4 cases of a heretofore undescribed soft-tissue tumor, which they called elastofibroma dorsi.The tumors were all located in the subscapttlar space adjacent to the apex of the scapula and beneath the rhomboid and latissimus dorsi muscles. Microscopically, there were large bands of dense, collagen-containing, swollen, fragmented elastic fibers and scattered islands of adipose tissue. All the subjects were elderly, and despite the infiltrative nature of the lesion, there were no recurrences after surgery.Subsequently, 3 additional cases have been reported, all in elderly persons and in the same characteristic anatomic location.2 , 3 The present . . .
FRI0111 Pulse methylprednisolone and cyclophosphamide therapy in three systemic lupus erythematosus patients with bronchiolitis obliterans organising pneumonia as the initial manifestation
Authors: JC Tseng, HH Cheng, RJ Hu, LY Lu
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Diverse pleuropulmonary manifestations are common in patients with systemic lupus erythematosus (SLE). Bronchilolitis obliterans organising pneumonia (BOOP) is a pathologic entity characterised by the formation of fibrous tissue plugs within terminal bronchioles and alveolar ducts. Although BOOP has been associated with several connective tissue disorders, there are rare reports of BOOP in patients of SLE as the initial manifestation. <h3>Objectives</h3> We describe three SLE patients with open lung biopsy-proved BOOP as the initial manifestation. All three cases presented with fever, cough and dyspnea. Chest radiographs and CT scan of lung revealed bilateral pulmonary infiltrates. BOOP was confirmed by open lung-biopsy. Pulmonary vasculitis was also demonstrated in lung histopathology in one case. <h3>Methods</h3> <h3>Results</h3> The pulmonary lesions and respiratory illnesses responsed well to pulse intravenous methylprednisolone and cyclophosphamide therapy. <h3>Conclusion</h3>
Bassoon Controls Presynaptic Autophagy through Atg5
Authors: Nathan D. Okerlund, Katharina Schneider, Sergio Leal-Ortiz, Carolina Montenegro-Venegas, Sally A. Kim, Loren C. Garner, Clarissa L. Waites, Eckart D. Gundelfinger, Richard J. Reimer, Craig C. Garner
Journal: Neuron (2018)
Digoxin: Corrigendum
Journal: BMJ (1933)

of your readers, especially in the Tropics, kindly let me know, through the columns of your Journal his experience of a preparation calledcl bilivaccine " as a prophylactic against enteric or cholera.This preparation is very ex- tensively advertised in India aInd is freely used by the public.My owN/n experience has Inot been very
THU0431 Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of medicare claims data
Authors: J Singh, J Cleveland
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Large scale randomized studies are underway to assess whether compared to placebo, each XO-inhibitor, allopurinol or febuxostat, can prevent renal function loss. This evidence is needed and will confirm their nephroprotective potential. However, neither study will answer a key question: Does the renal protective effect of allopurinol differ from that of febuxostat? <h3>Objectives</h3> To assess the comparative effectiveness of allopurinol vs. febuxostat for preventing incident renal disease in elderly. <h3>Methods</h3> In a retrospective cohort study using Medicare claims data, we included patients newly treated with allopurinol or febuxostat (baseline period of 183 days without either medication). We used 1:5 propensity-matched Cox regression analyses to compare the hazard ratio (HR) of incident renal disease with allopurinol use and allopurinol dose vs. febuxostat (reference category). Sensitivity analyses included multivariable-adjusted regression models. <h3>Results</h3> There were 31,465 new allopurinol or febuxostat treatment episodes in 26,443 patients; 8,570 ended in incident renal disease. Crude rates of incident renal disease per 100,000 person-days were 53 with allopurinol vs. 93 with febuxostat. Crude rates of incident renal disease per 100,000 person-days were lower with higher daily dose: allopurinol &lt;200, 200–299 and ≥300 mg/day with 65, 48 and 43; and febuxostat 40 mg and 80 mg/day with 93 and 89, respectively. In propensity-matched analyses, compared to febuxostat use, allopurinol use was associated with lower HR of incident renal disease, 0.61 (95% confidence interval (CI): 0.49, 0.77). Compared to febuxostat 40 mg/day, allopurinol doses &lt;200, 200–299 and ≥300 mg/day were associated with lower HR of incident renal disease, 0.75 (95% CI: 0.65, 0.86), 0.61 (95% CI: 0.52, 0.73) and 0.48 (95% CI: 0.41, 0.55), respectively. Sensitivity analyses using multivariable-adjusted regression confirmed these findings. <h3>Conclusions</h3> Allopurinol was more effective than febuxostat in preventing incident renal disease in elderly patients. Future studies need to examine the mechanism of this renal benefit of allopurinol. <h3>Disclosure of Interest</h3> J. Singh Grant/research support from: Savient, Takeda, Consultant for: Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology, J. Cleveland: None declared
Abstract 469: Altered Plasma vs. Vascular Biopterins In Human Atherosclerosis Reveal Relationships Between Endothelial Nitric Oxide Synthase Coupling, Endothelial Function And Inflammation
Authors: Charalambos Antoniades, Cheerag Shirodaria, Paul Leeson, Mark Crabtree, Ravi Pillai, Chandi Ratnatunga, Dimitris Tousoulis, Christodoulos Stefanadis, Keith M Channon
Journal: Circulation (2007)

Introduction: Tetrahydrobiopterin (BH4) is a regulator of endothelial nitric oxide synthase (eNOS) coupling but its synthesis is also stimulated by inflammation in experimental models. We defined for the first time, the relationships between plasma and vascular biopterins in patients with coronary artery disease, and we determined the impact of BH4 on endothelial function, eNOS coupling, and O2- production in human vessels. Methods : Paired samples of saphenous veins (SV) and internal mammary arteries (IMA) were obtained from 219 patients undergoing coronary bypass surgery. Vasomotor responses to acetylcholine (Ach) were determined ex-vivo and vascular O2- (± the eNOS inhibitor LNAME) was measured by chemiluminescence. Biopterins were measured by HPLC. Results: High vascular BH4 was associated with better vasorelaxations of SV to Ach, whereas high plasma BH4 was associated with worse vasorelaxations (Fig. a-b ). There was an inverse association between plasma and vascular biopterins (Fig c ). High vascular (but not plasma) BH4 was associated with lower O2-and less L-NAME inhibitable O2- (suggesting better eNOS coupling) in both SV and IMA (Fig c ). Finally, serum C-reactive protein was correlated with plasma biopterins (r=0.268, p=0.001) but not with vascular biopterins in SV (r=0.02, p=0.0857) or IMA (r=−0.044, p=0.717). Conclusions : There is an inverse association between plasma and vascular biopterins in patients with atherosclerosis. Vascular but not plasma BH4 is a modulator of NO bioavailability and eNOS coupling in human vessels, while plasma total biopterin is rather a marker of systemic inflammation, than a regulator of vascular function in vivo.
"MEN IN WHITE"
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease
Authors: F Jardin, M Callanan, D Penther, P Ruminy, X Troussard, J P Kerckaert, M Figeac, F Parmentier, V Rainville, I Vaida, P Bertrand, A B Duval, J M Picquenot, L Chaperot, J P Marolleau, J Plumas, H Tilly, C Bastard
Journal: Leukemia (2009)
Journal American Dental Association, Chicago
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PROTEIN AND IMMUNITY
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Information of APPLE 2017
Authors: Masatoshi Kudo, Masatoshi Kudo, Byung Ihn Choi, Hyun Jeong Park, Eun Sun Lee, Sung Bin Park, Jong Beum Lee, Helen M. Parsons, Quyen Chu, Jordan J. Karlitz, Jennifer L. Stevens, Linda C. Harlan, Tatsuya Yamashita, Takeshi Terashima, Kuniaki Arai, Kazunori Kawaguchi, Kazuya Kitamura, Taro Yamashita, Yoshio Sakai, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko, Takashi Kumada, Masatoshi Kudo, Masashi Hirooka, Kunihiko Tsuji, Ei Itobayashi, Kazuya Kariyama, Toru Ishikawa, Kazuto Tajiri, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Hideki Kawasaki, Yoichi Hiasa, Kojiro Michitaka, Atsushi Hiraoka, Hironori Ochi, Kouji Joko, Tadaaki Arizumi, Kazuomi Ueshima, Mina Iwanishi, Tomohiro Minami, Hirokazu Chishina, Masashi Kono, Masahiro Takita, Norihisa Yada, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Yoriaki Komeda, Mamoru Takenaka, Toshiharu Sakurai, Tomohiro Watanabe, Naoshi Nishida, Masatoshi Kudo, Mengensatzproduktion, Druckerei Stückle, Druckerei Stückle, on behalf of the Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics)
Journal: Liver Cancer (2017)
WHERE ARE THE BILE PIGMENTS FORMED?
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Food and Drug Administration
Authors: S L Nightingale
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation for exercise participation. The apparently healthy individual
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal